|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hellman K, Silfversward C, Nilsson B,
Hellstrom AC, Frankendal B and Pettersson F: Primary carcinoma of
the vagina: factors influencing the age at diagnosis. The
Radiumhemmet series 1956–96. Int J Gynecol Cancer. 14:491–501.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hacker NF, Eifel PJ and van der Velden J:
Cancer of the vagina. Int J Gynaecol Obstet. 131 (Suppl 2):S84–S87.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghezelayagh T, Rauh-Hain JA and Growdon
WB: Comparing mortality of vaginal sarcoma, squamous cell
carcinoma, and adenocarcinoma in the surveillance, epidemiology,
and end results database. Obstet Gynecol. 125:1353–1361. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hiniker SM, Roux A, Murphy JD, Harris JP,
Tran PT, Kapp DS and Kidd EA: Primary squamous cell carcinoma of
the vagina: Prognostic factors, treatment patterns, and outcomes.
Gynecol Oncol. 131:380–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shah CA, Goff BA, Lowe K, Peters WA III
and Li CI: Factors affecting risk of mortality in women with
vaginal cancer. Obstet Gynecol. 113:1038–1045. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gadducci A, Fabrini MG, Lanfredini N and
Sergiampietri C: Squamous cell carcinoma of the vagina: Natural
history, treatment modalities and prognostic factors. Crit Rev
Oncol Hematol. 93:211–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hellman K, Lundell M, Silfversward C,
Nilsson B, Hellstrom AC and Frankendal B: Clinical and
histopathologic factors related to prognosis in primary squamous
cell carcinoma of the vagina. Int J Gynecol Cancer. 16:1201–1211.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Larsson GL, Helenius G, Andersson S, Sorbe
B and Karlsson MG: Prognostic impact of human papilloma virus (HPV)
genotyping and HPV-16 subtyping in vaginal carcinoma. Gynecol
Oncol. 129:406–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hellman K, Lindquist D, Ranhem C, Wilander
E and Andersson S: Human papillomavirus, p16(INK4A), and Ki-67 in
relation to clinicopathological variables and survival in primary
carcinoma of the vagina. Br J Cancer. 110:1561–1570. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hayflick L: The illusion of cell
immortality. Br J Cancer. 83:841–846. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blackburn EH: Switching and signaling at
the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nguyen THD, Collins K and Nogales E:
Telomerase structures and regulation: Shedding light on the
chromosome end. Curr Opin Struct Biol. 55:185–193. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Venteicher AS, Abreu EB, Meng Z, McCann
KE, Terns RM, Veenstra TD, Terns MP and Artandi SE: A human
telomerase holoenzyme protein required for Cajal body localization
and telomere synthesis. Science. 323:644–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mahmoudi S, Henriksson S, Weibrecht I,
Smith S, Söderberg O, Strömblad S, Wiman KG and Farnebo M: WRAP53
is essential for Cajal body formation and for targeting the
survival of motor neuron complex to Cajal bodies. PLoS Biol.
8:e10005212010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Montanaro L, Brigotti M, Clohessy J,
Barbieri S, Ceccarelli C, Santini D, Taffurelli M, Calienni M,
Teruya-Feldstein J, Trerè D, et al: Dyskerin expression influences
the level of ribosomal RNA pseudo-uridylation and telomerase RNA
component in human breast cancer. J Pathol. 210:10–18. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Montanaro L, Calienni M, Bertoni S, Rocchi
L, Sansone P, Storci G, Santini D, Ceccarelli C, Taffurelli M,
Carnicelli D, et al: Novel dyskerin-mediated mechanism of p53
inactivation through defective mRNA translation. Cancer Res.
70:4767–4777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang M, Pan Y, Jiang R, Hou P, Shan H,
Chen F, Jiang T, Bai J and Zheng J: DKC1 serves as a potential
prognostic biomarker for human clear cell renal cell carcinoma and
promotes its proliferation, migration and invasion via the NF-κB
pathway. Oncol Rep. 40:968–978. 2018.PubMed/NCBI
|
|
19
|
Bellodi C, Krasnykh O, Haynes N,
Theodoropoulou M, Peng G, Montanaro L and Ruggero D: Loss of
function of the tumor suppressor DKC1 perturbs p27 translation
control and contributes to pituitary tumorigenesis. Cancer Res.
70:6026–6035. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miao FA, Chu K, Chen HR, Zhang M, Shi PC,
Bai J and You YP: Increased DKC1 expression in glioma and its
significance in tumor cell proliferation, migration and invasion.
Invest New Drugs. 37:1177–1186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu B, Zhang J, Huang C and Liu H:
Dyskerin overexpression in human hepatocellular carcinoma is
associated with advanced clinical stage and poor patient prognosis.
PLoS One. 7:e431472012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Penzo M, Ludovini V, Treré D, Siggillino
A, Vannucci J, Bellezza G, Crinò L and Montanaro L: Dyskerin and
TERC expression may condition survival in lung cancer patients.
Oncotarget. 6:21755–21760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
O'Brien R, Tran SL, Maritz MF, Liu B, Kong
CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, et al:
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent
Function of Dyskerin. Cancer Res. 76:3604–3617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahmoudi S, Henriksson S, Corcoran M,
Méndez-Vidal C, Wiman KG and Farnebo M: Wrap53, a natural p53
antisense transcript required for p53 induction upon DNA damage.
Mol Cell. 33:462–471. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Henriksson S, Rassoolzadeh H, Hedström E,
Coucoravas C, Julner A, Goldstein M, Imreh G, Zhivotovsky B, Kastan
MB, Helleday T, et al: The scaffold protein WRAP53β orchestrates
the ubiquitin response critical for DNA double-strand break repair.
Genes Dev. 28:2726–2738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garvin S, Tiefenböck K, Farnebo L, Thunell
LK, Farnebo M and Roberg K: Nuclear expression of WRAP53β is
associated with a positive response to radiotherapy and improved
overall survival in patients with head and neck squamous cell
carcinoma. Oral Oncol. 51:24–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Silwal-Pandit L, Russnes H, Borgen E,
Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B,
Børresen-Dale AL, Farnebo M, et al: The Sub-Cellular Localization
of WRAP53 Has Prognostic Impact in Breast Cancer. PLoS One.
10:e01399652015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hedström E, Pederiva C, Farnebo J, Nodin
B, Jirström K, Brennan DJ and Farnebo M: Downregulation of the
cancer susceptibility protein WRAP53β in epithelial ovarian cancer
leads to defective DNA repair and poor clinical outcome. Cell Death
Dis. 6:e18922015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bergstrand S, O'Brien EM and Farnebo M:
The Cajal Body Protein WRAP53β Prepares the Scene for Repair of DNA
Double-Strand Breaks by Regulating Local Ubiquitination. Front Mol
Biosci. 6:512019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Henriksson S and Farnebo M: On the road
with WRAP53β: Guardian of Cajal bodies and genome integrity. Front
Genet. 6:912015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang H, Wang DW, Adell G and Sun XF:
WRAP53 is an independent prognostic factor in rectal cancer- a
study of Swedish clinical trial of preoperative radiotherapy in
rectal cancer patients. BMC Cancer. 12:2942012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rao X and Huang D, Sui X, Liu G, Song X,
Xie J and Huang D: Overexpression of WRAP53 is associated with
development and progression of esophageal squamous cell carcinoma.
PLoS One. 9:e916702014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu Y, Ding L, Chen BF, Song JG and Yao
YS: Oncogenic Activity of Wrap53 in Human Colorectal Cancer In
Vitro and in Nude Mouse Xenografts. Med Sci Monit. 24:6129–6136.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Herrington SC and Ordi J: Chapter 34:
Tumours of the vagina. In: WHO Classification of Tumours: Female
genital tumours. (5th edition). 4:WHO Classification of Tumours
Editorial Board (ed), IARC Press. (Lyon, France). 2020.
|
|
35
|
Sieron P, Hader C, Hatina J, Engers R,
Wlazlinski A, Müller M and Schulz WA: DKC1 overexpression
associated with prostate cancer progression. Br J Cancer.
101:1410–1416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Montanaro L, Calienni M, Ceccarelli C,
Santini D, Taffurelli M, Pileri S, Treré D and Derenzini M:
Relationship between dyskerin expression and telomerase activity in
human breast cancer. Cell Oncol. 30:483–490. 2008.PubMed/NCBI
|
|
37
|
Bellodi C, McMahon M, Contreras A, Juliano
D, Kopmar N, Nakamura T, Maltby D, Burlingame A, Savage SA,
Shimamura A, et al: H/ACA small RNA dysfunctions in disease reveal
key roles for noncoding RNA modifications in hematopoietic stem
cell differentiation. Cell Rep. 3:1493–1502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heiss NS, Knight SW, Vulliamy TJ, Klauck
SM, Wiemann S, Mason PJ, Poustka A and Dokal I: X-linked
dyskeratosis congenita is caused by mutations in a highly conserved
gene with putative nucleolar functions. Nat Genet. 19:32–38. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Poncet D, Belleville A, t'kint de
Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H,
Callet-Bauchu E, Salles G, Sabatier L, Delic J, et al: Changes in
the expression of telomere maintenance genes suggest global
telomere dysfunction in B-chronic lymphocytic leukemia. Blood.
111:2388–2391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Katzenellenbogen R: Telomerase Induction
in HPV Infection and Oncogenesis. Viruses. 9:E1802017. View Article : Google Scholar
|
|
41
|
Klingelhutz AJ, Foster SA and McDougall
JK: Telomerase activation by the E6 gene product of human
papillomavirus type 16. Nature. 380:79–82. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Koskimaa HM, Kurvinen K, Costa S, Syrjänen
K and Syrjänen S: Molecular markers implicating early malignant
events in cervical carcinogenesis. Cancer Epidemiol Biomarkers
Prev. 19:2003–2012. 2010. View Article : Google Scholar : PubMed/NCBI
|
